Allied Patients, a US-based development and manufacturing network, has launched as a new company to develop affordable generic medications. Eduardo Matto, MD, a military physician, is chief executive officer and founder of the company.

Allied Patients says it seeks to streamline the way medications are produced and distributed in order to reduce price barriers between patients and treatments. The company says it relies on a distributed development and manufacturing network that can develop a generic medication and complete bioequivalence studies in 12 months. All development work and bioequivalence studies are done in the US to ensure US Food and Drug Administration regulations are met with quality monitoring throughout the process.

The company estimates that there are over 500 branded medications without a generic alternative and is seeking to supply generic products in those areas.

Source: Allied Patients